z-logo
open-access-imgOpen Access
Prognostic significance of poorly differentiated histology and impact of adjuvant chemotherapy in early squamous cell carcinoma of cervix uteri
Author(s) -
Luo Hui,
Yao Hongxia,
Xu Xinxin,
Li Zhen,
Zhao Hongqin,
Zhu Haiyan
Publication year - 2021
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.3780
Subject(s) - medicine , chemotherapy , cervical cancer , oncology , cisplatin , cervix , radical hysterectomy , hazard ratio , squamous carcinoma , stage (stratigraphy) , cancer , carcinoma , confidence interval , paleontology , biology
Objective This study is to determine whether the addition of cisplatin‐based chemotherapy after radical hysterectomy will improve the survival of low‐risk squamous cervical carcinoma with poor differentiation. Methods Patients with low‐risk squamous cervical cancer (FIGO IA2–IIA, absent high‐ and intermediate‐risk factors after pathological evaluation) were eligible for this study. As first, the prognostic relevance of G3 versus G1/G2 among patients with low‐risk squamous cervical cancer was analyzed, then, the oncological results of postoperative chemotherapy among low‐risk squamous cervical cancer with poor differentiation was explored. Results Totally, there were 367 low‐risk squamous cervical cancer patients, of whom 161 were poor‐differentiated (47 in the chemotherapy group and 114 in the nonchemotherapy group), with a median follow‐up time of 56 months. Patients with G3 displayed a significantly worse overall survival ( p  = 0.035), and a higher recurrence rate ( p  = 0.014) than patients with G1/G2. Compared with the nonchemotherapy group, the hazard ratios (95%CI) for recurrence‐free survival in the chemotherapy group was 0.24 (0.06–0.93), ( p  = 0.038). No difference in overall survival was observed between the chemotherapy group and the nonchemotherapy group. Conclusions The addition of cisplatin‐based chemotherapy following surgery significantly improved recurrence‐free survival for low‐risk, poor differentiation, and early stage squamous cervical cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here